Presentation
Preclinical study of cytotoxicity and predictive markers of response to dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 with or without paclitaxel or nab-paclitaxel as a new therapeutic strategy in pancreatic cancer cell lines
American Society of Clinical Oncology (ASCO) Annual Meeting
(2013)
Disciplines
Publication Date
2013
Location
Chicago, IL
Comments
Additional authors: A. Loaiza-Bonilla, M. Kittaneh, K. Kovacs, J.R. Merchan
Citation Information
Victor D Guardiola Amado. "Preclinical study of cytotoxicity and predictive markers of response to dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 with or without paclitaxel or nab-paclitaxel as a new therapeutic strategy in pancreatic cancer cell lines" American Society of Clinical Oncology (ASCO) Annual Meeting (2013) Available at: http://works.bepress.com/victor-guardiolaamado/5/